Zoetis Inc Cl A (NYSE:ZTS)

From 12/17/2018:

"It's not difficult to make a case for the long-term prospects of Zoetis. The company is comfortably profitable, growing at a healthy clip in recession-proof markets, and boasts multiple shots on goal in high-growth opportunities. While the growth potential is undeniable, so is the fact that Zoetis stock is very expensive. It trades at 28 times future earnings, 20 times book value, and 21 times enterprise value to EBITDA -- all significantly higher than its more traditional pharmaceutical peers.

That said, comparing the animal health leader to human-health peers may not make much sense. A more apt comparison is Elanco Animal Health, which just made its debut on the stock markets in summer 2018. However, the smaller peer has a different portfolio mix and, following years of reshuffling assets, is still largely unproven in its current form. Essentially, there aren't any great head-to-head comparisons to make today.

Although the stock is rather expensive, investors who believe in the long-term growth potential of Zoetis may not hesitate to begin building a position in the company, especially if there's a pullback."

https://www.fool.com/investing/2018/12/17/is-it-too-late-to-get-in-on-this-millionaire-maker.aspx

Millennials love their pets. Animal care and diagnostics is a basket I believe has long tail winds.